<SEC-DOCUMENT>0001157523-15-000632.txt : 20150219
<SEC-HEADER>0001157523-15-000632.hdr.sgml : 20150219
<ACCEPTANCE-DATETIME>20150219160556
ACCESSION NUMBER:		0001157523-15-000632
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		2
CONFORMED PERIOD OF REPORT:	20150217
ITEM INFORMATION:		Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20150219
DATE AS OF CHANGE:		20150219

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Anika Therapeutics, Inc.
		CENTRAL INDEX KEY:			0000898437
		STANDARD INDUSTRIAL CLASSIFICATION:	SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
		IRS NUMBER:				043145961
		STATE OF INCORPORATION:			MA
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-14027
		FILM NUMBER:		15631794

	BUSINESS ADDRESS:	
		STREET 1:		32 WIGGINS AVENUE
		CITY:			BEDFORD
		STATE:			MA
		ZIP:			01730
		BUSINESS PHONE:		(781) 457-9000

	MAIL ADDRESS:	
		STREET 1:		32 WIGGINS AVENUE
		CITY:			BEDFORD
		STATE:			MA
		ZIP:			01730

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ANIKA THERAPEUTICS INC
		DATE OF NAME CHANGE:	19970114

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ANIKA RESEARCH INC
		DATE OF NAME CHANGE:	19930309
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>a51043717.htm
<DESCRIPTION>ANIKA THERAPEUTICS, INC. 8-K
<TEXT>
<html>
  <head>
    <title></title>
<!--Copyright 2015 Business Wire, a Berkshire Hathaway company.-->
<!--All rights reserved www.businesswire.com-->
  </head>
  <body style="font-family: Times New Roman; font-size: 10pt">
    <p style="text-align: center">

    </p>
    <p style="text-align: center">
      <font style="font-size: 16pt; font-family: Times New Roman">UNITED STATES</font><font style="font-size: 16pt; font-family: Times New Roman"><br style="font-family: Times New Roman; font-size: 16pt"></font><font style="font-size: 16pt; font-family: Times New Roman">SECURITIES
      AND EXCHANGE COMMISSION</font><br><font style="font-size: 11pt">Washington,
      D.C. 20549</font><font style="font-size: 11pt"><br style="font-size: 11pt"></font><font style="font-size: 11pt"><br style="font-size: 11pt"></font><font style="font-size: 16pt; font-family: Times New Roman">FORM
      8-K</font><font style="font-size: 11pt"><br style="font-size: 11pt"></font><font style="font-size: 11pt"><br style="font-size: 11pt"></font><font style="font-size: 11pt">CURRENT
      REPORT</font><font style="font-size: 11pt"><br style="font-size: 11pt"></font><font style="font-size: 11pt">PURSUANT
      TO SECTION 13 OR 15(d)</font><br><font style="font-size: 11pt">OF THE
      SECURITIES EXCHANGE ACT OF 1934</font><font style="font-size: 11pt"><br style="font-size: 11pt"></font><font style="font-size: 11pt"><br style="font-size: 11pt"></font><font style="font-size: 11pt; font-family: Times New Roman">Date
      of Report (Date of earliest event reported): February 17, 2015</font><font style="font-size: 11pt"><br style="font-size: 11pt"></font><font style="font-size: 11pt"><br style="font-size: 11pt"></font><font style="font-size: 16pt">Anika
      Therapeutics, Inc.</font><font style="font-size: 11pt"><br style="font-size: 11pt"></font><font style="font-size: 10pt">(</font><i><font style="font-size: 10pt">Exact
      Name of Registrant as Specified in Charter</font></i><font style="font-size: 10pt">)</font>
    </p>
    <hr style="color: #000000; text-align: center; width: 40%; height: 1.0 pt">


    <p style="text-align: center">

    </p>
    <div style="text-align:center">
    <table style="margin-left:auto;margin-right:auto; margin-bottom: 10.0px; font-family: Times New Roman; font-size: 10pt; width: 100%" cellspacing="0">
      <tr>
        <td style="text-align: center; padding-left: 0.0px; width: 33%" valign="bottom">
          <p style="margin-bottom: 0px; margin-top: 0px">
            Massachusetts
          </p>
        </td>
        <td style="text-align: center; padding-right: 0.0px; padding-left: 0.0px; white-space: nowrap; width: 34%" valign="bottom">
          <p style="margin-bottom: 0px; margin-top: 0px">
            000-21326
          </p>
        </td>
        <td style="text-align: center; padding-right: 0.0px; padding-left: 0.0px; white-space: nowrap; width: 33%" valign="bottom">
          <p style="margin-bottom: 0px; margin-top: 0px">
            04-314-5961
          </p>
        </td>
      </tr>
      <tr>
        <td style="text-align: center; padding-left: 0.0px; width: 33%" valign="top">
          <p style="margin-bottom: 0px; margin-top: 0px">
            <i>(State or Other Jurisdiction</i><br><i>of Incorporation)</i>
          </p>
        </td>
        <td style="text-align: center; padding-left: 0.0px; width: 34%" valign="top">
          <p style="margin-bottom: 0px; margin-top: 0px">
            <i>(Commission</i><br><i>File Number)</i>
          </p>
        </td>
        <td style="text-align: center; padding-left: 0.0px; width: 33%" valign="top">
          <p style="margin-bottom: 0px; margin-top: 0px">
            <i>(I.R.S. Employer<br>Identification No.)</i>
          </p>
        </td>
      </tr>
    </table>
    </div>
    <p>

    </p>
    <div style="text-align:center">
    <table style="margin-left:auto;margin-right:auto; margin-bottom: 10.0px; font-size: 10pt; font-family: Times New Roman; width: 100%" cellspacing="0">
      <tr>
        <td style="text-align: center; padding-right: 0.0px; padding-left: 0.0px; white-space: nowrap" valign="top">
          <p style="margin-bottom: 0px; margin-top: 0px">
            32 Wiggins Avenue, Bedford, MA 01730
          </p>
        </td>
      </tr>
      <tr>
        <td style="text-align: center; padding-left: 0.0px" valign="top">
          <p style="margin-bottom: 0px; margin-top: 0px">
            <i>(Address of Principal Executive Offices) (Zip Code)</i>
          </p>
        </td>
      </tr>
    </table>
    </div>
    <p style="text-align: center; white-space: nowrap">
      <br>
      <i><font style="font-family: Times New Roman; font-size: 10pt">Registrant&#8217;s
      telephone number, including area code:&#160;&#160;&#160;</font></i><font style="font-family: Times New Roman; font-size: 10pt">781-457-9000</font><br><br><br>
    </p>
    <p style="text-align: center">
      <i><font style="font-family: Times New Roman; font-size: 10pt">(Former
      name or former address, if changed since last report.)</font></i><br>
    </p>
    <hr style="text-align: center; height: 1.0 pt; color: #000000; width: 40%">


    <p>

    </p>
    <p>
      <font style="font-family: Times New Roman; font-size: 10pt">Check the
      appropriate box below if the Form 8-K filing is intended to
      simultaneously satisfy the filing obligation of the registrant under any
      of the following provisions:</font>
    </p>
    <p>
      <font style="font-family: Arial Unicode MS; font-size: 10pt">&#8414;</font>
      <font style="font-family: Times New Roman; font-size: 10pt">Written
      communications pursuant to Rule 425 under the Securities Act (17 CFR
      230.425)</font>
    </p>
    <p>
      <font style="font-family: Arial Unicode MS; font-size: 10pt">&#8414;</font>
      <font style="font-family: Times New Roman; font-size: 10pt">Soliciting
      material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
      240.14a-12)</font>
    </p>
    <p>
      <font style="font-family: Arial Unicode MS; font-size: 10pt">&#8414;</font>
      <font style="font-family: Times New Roman; font-size: 10pt">Pre-commencement
      communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR
      240.14d-2(b))</font>
    </p>
    <p>
      <font style="font-family: Arial Unicode MS; font-size: 10pt">&#8414;</font>
      <font style="font-family: Times New Roman; font-size: 10pt">Pre-commencement
      communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR
      240.13e-4(c))</font>
    </p>
    <p>

    </p>
    <div style="margin-left: 0pt; text-indent: 0pt; margin-bottom: 10pt; margin-right: 0pt; width: 100%">
      <div>
        <div style="text-align: left">

        </div>
      </div>
      <div style="page-break-after: always">
        <div style="text-align: center">

        </div>
        <div style="text-align: center">
          <hr style="height: 1.5pt; color: black">

        </div>
      </div>
      <div>
        <div style="text-align: right">

        </div>
      </div>
    </div>
    <p>

    </p>
<div style="text-align:left">
    <table style="margin-bottom: 10.0px; font-size: 10pt; font-family: Times New Roman; width: 100%" cellspacing="0">
      <tr>
        <td style="text-align: left; padding-left: 0.0px; width: 15%" valign="top">
          <p style="margin-bottom: 0px; margin-top: 0px">
            <b>Item 5.02</b>
          </p>
        </td>
        <td style="text-align: left; padding-left: 0.0px; width: 85%" valign="top">
          <p style="margin-bottom: 0px; margin-top: 0px">
            <b>Departure of Directors or Certain Officers; Election of
            Directors; Appointment of Certain Officers; Compensatory
            Arrangements of Certain Officers</b>
          </p>
        </td>
      </tr>
    </table>
    </div>
<div style="text-align:left">
    <table style="margin-bottom: 10.0px; font-size: 10pt; font-family: Times New Roman; width: 100%" cellspacing="0">
      <tr>
        <td style="text-align: left; padding-left: 0.0px; width: 15%" valign="top">
          &#160;
        </td>
        <td style="text-align: left; padding-left: 0.0px; width: 85%" valign="top">
          (d) Election of Dr. Glenn R. Larsen to the board of directors
        </td>
      </tr>
    </table>
    </div>
    <p style="text-indent: 30.0px">
      On February 17, 2015, the board of directors elected Glenn R. Larsen,
      Ph.D., as one of our Class I directors, effective as of 5 p.m. on
      February 17, 2015.&#160;&#160;As a Class I director, Dr. Larsen&#8217;s term will expire
      at the 2015 Annual Meeting of Stockholders.&#160;&#160;The board has voted to
      nominate Dr. Larsen for election by the stockholders at the 2015 Annual
      Meeting.&#160;&#160;In addition, Dr. Larsen was appointed to the board&#8217;s
      compensation committee and to its governance and nominating committee,
      effective February 18, 2015.
    </p>
    <p style="text-indent: 30.0px">
      In connection with his election to the board, Dr. Larsen was awarded
      2,122 restricted stock units under our Second Amended and Restated 2003
      Stock Option and Incentive Plan.&#160;&#160;Each restricted stock unit gives Dr.
      Larsen the right to receive one share of our common stock and is valued
      at $42.40 per unit, the fair market value of a share of our common stock
      on February 17, 2015.&#160;&#160;The restricted stock units will vest in full on
      February 17, 2016.&#160;&#160;
    </p>
    <p style="text-indent: 30.0px">
      Dr. Larsen, age 60, is Chief Executive Officer of Aquinnah
      Pharmaceuticals, Inc., a pharmaceutical company focused on the
      development of treatments for neurodegenerative diseases, which he
      co-founded in February 2014. He also is a co-founder and Chairman of the
      Board of Directors of 180 Therapeutics L.P., a clinical stage drug
      delivery and development company founded in 2013. He previously served
      as Chief Scientific Officer and Executive Vice President of Research and
      Development at SpringLeaf Therapeutics, Inc., a producer of drug
      delivery devices, and at Hydra Biosciences, Inc., a biopharmaceutical
      company, as Chief Operating Officer, Executive Vice President of
      Development, and a member of its board of directors. During his prior
      employment at Wyeth/Genetics Institute, Dr. Larsen served in various
      research and development leadership positions, including directing
      Wyeth&#8217;s second largest therapeutic area as Vice President
      Musculoskeletal Sciences. Dr. Larsen received his Ph.D. in Biochemistry
      from Stony Brook University and is a graduate of the Program for
      Management Development at Harvard University Graduate School of
      Business.&#160;&#160;
    </p>
    <p style="text-indent: 30.0px">
      A copy of the press release issued on February 19, 2015, announcing the
      election of Dr. Larsen to the board is filed as Exhibit 99.1 hereto and
      incorporated herein by reference.
    </p>
    <p>

    </p>
<div style="text-align:left">
    <table style="margin-bottom: 10.0px; font-size: 10pt; font-family: Times New Roman; width: 100%" cellspacing="0">
      <tr>
        <td style="text-align: left; padding-left: 0.0px; width: 15%" valign="top">
          <p style="margin-bottom: 0px; margin-top: 0px">
            <b>Item 9.01</b>
          </p>
        </td>
        <td style="text-align: left; padding-left: 0.0px; width: 85%" valign="top">
          <p style="margin-bottom: 0px; margin-top: 0px">
            <b>Financial Statements and Exhibits</b>
          </p>
        </td>
      </tr>
    </table>
    </div>
<div style="text-align:left">
    <table style="margin-bottom: 10.0px; font-size: 10pt; font-family: Times New Roman; width: 100%" cellspacing="0">
      <tr>
        <td style="text-align: left; padding-left: 0.0px; width: 15%" valign="top">
          &#160;
        </td>
        <td style="text-align: left; padding-left: 0.0px; width: 85%" valign="top">
          (d) Exhibits
        </td>
      </tr>
    </table>
    </div>
    <p style="text-indent: 30.0px">
      The following exhibit is filed as part of this report:
    </p>
<div style="text-align:left">
    <table style="margin-bottom: 10.0px; font-size: 10pt; font-family: Times New Roman; width: 100%" cellspacing="0">
      <tr>
        <td style="text-align: center; border-bottom: solid black 1.0pt; padding-left: 0.0px; width: 13%" valign="bottom">
          <b>Exhibit No.</b>
        </td>
        <td style="text-align: center; padding-bottom: 2.0px; padding-left: 0.0px; width: 2%" valign="bottom">
          &#160;
        </td>
        <td style="text-align: center; border-bottom: solid black 1.0pt; padding-left: 0.0px; width: 85%" valign="bottom">
          <b>Description</b>
        </td>
      </tr>
      <tr>
        <td style="text-align: center; padding-left: 0.0px; width: 13%" valign="top">

        </td>
        <td style="text-align: left; padding-left: 0.0px; width: 2%" valign="bottom">

        </td>
        <td style="text-align: left; padding-left: 0.0px; width: 85%" valign="top">
          &#160;
        </td>
      </tr>
      <tr>
        <td style="text-align: center; padding-right: 0.0px; padding-left: 0.0px; white-space: nowrap; width: 13%" valign="top">
          99.1
        </td>
        <td style="text-align: left; padding-left: 0.0px; width: 2%" valign="bottom">

        </td>
        <td style="text-align: left; padding-left: 0.0px; width: 85%" valign="top">
          Press release issued by Anika Therapeutics, Inc. on February 19, 2015
        </td>
      </tr>
    </table>
    </div>
    <p>

    </p>
    <div style="margin-left: 0pt; text-indent: 0pt; margin-bottom: 10pt; margin-right: 0pt; width: 100%">
      <div>
        <div style="text-align: left">

        </div>
      </div>
      <div style="page-break-after: always">
        <div style="text-align: center">

        </div>
        <div style="text-align: center">
          <hr style="height: 1.5pt; color: black">

        </div>
      </div>
      <div>
        <div style="text-align: right">

        </div>
      </div>
    </div>
    <p>

    </p>
    <p style="text-align: center">
      <font style="font-family: Times New Roman; font-size: 10pt"><b>SIGNATURE</b></font><br>
    </p>
    <p style="text-indent: 30.0px; font-size: 10pt; font-family: Times New Roman">
      Pursuant to the requirements of the Securities Exchange Act of 1934, the
      registrant has duly caused this report to be filed on its behalf by the
      undersigned hereunto duly authorized.
    </p>
    <p style="text-indent: 30.0px; font-size: 10pt; font-family: Times New Roman">

    </p>
    <div style="text-align:center">
    <table style="margin-left:auto;margin-right:auto; margin-bottom: 10.0px; font-size: 10pt; font-family: Times New Roman; width: 100%" cellspacing="0">
      <tr>
        <td style="width: 50%">

        </td>
        <td colspan="3" style="text-align: left; padding-left: 0.0px" valign="top">
          <p style="margin-bottom: 0px; margin-top: 0px">
            ANIKA THERAPEUTICS, INC.
          </p>
        </td>
      </tr>
      <tr>
        <td style="width: 50%">

        </td>
        <td style="text-align: left; padding-left: 0.0px; width: 3%" valign="top">
          <p style="margin-bottom: 0px; margin-top: 0px">
            &#160;
          </p>
        </td>
        <td style="width: 37%">

        </td>
        <td style="width: 10%">

        </td>
      </tr>
      <tr>
        <td style="text-align: left; padding-bottom: 2.0px; padding-left: 0.0px; width: 50%" valign="top">
          <p style="margin-bottom: 0px; margin-top: 0px">
            Dated: February 19, 2015
          </p>
        </td>
        <td style="text-align: left; padding-bottom: 2.0px; padding-left: 0.0px; width: 3%" valign="top">
          By:
        </td>
        <td style="text-align: left; border-bottom: solid black 1.0pt; padding-left: 0.0px; width: 37%" valign="top">
          <p style="margin-bottom: 0px; margin-top: 0px">
            /s/ SYLVIA CHEUNG
          </p>
        </td>
        <td style="width: 10%">

        </td>
      </tr>
      <tr>
        <td style="width: 50%">

        </td>
        <td style="text-align: left; padding-left: 0.0px; width: 3%" valign="top">
          <p style="margin-bottom: 0px; margin-top: 0px">
            &#160;
          </p>
        </td>
        <td style="text-align: left; padding-left: 0.0px; width: 37%" valign="top">
          <p style="margin-bottom: 0px; margin-top: 0px">
            Sylvia Cheung
          </p>
        </td>
        <td style="width: 10%">

        </td>
      </tr>
      <tr>
        <td style="width: 50%">

        </td>
        <td style="text-align: left; padding-left: 0.0px; width: 3%" valign="top">
          <p style="margin-bottom: 0px; margin-top: 0px">
            &#160;
          </p>
        </td>
        <td style="text-align: left; padding-left: 0.0px; width: 37%" valign="top">
          <p style="margin-bottom: 0px; margin-top: 0px">
            Chief Financial Officer
          </p>
        </td>
        <td style="width: 10%">

        </td>
      </tr>
    </table>
    </div>
    <p>

    </p>
    <div style="margin-left: 0pt; text-indent: 0pt; margin-bottom: 10pt; margin-right: 0pt; width: 100%">
      <div>
        <div style="text-align: left">

        </div>
      </div>
      <div style="page-break-after: always">
        <div style="text-align: center">

        </div>
        <div style="text-align: center">
          <hr style="height: 1.5pt; color: black">

        </div>
      </div>
      <div>
        <div style="text-align: right">

        </div>
      </div>
    </div>
    <p>

    </p>
    <p style="text-align: center">
      <b>EXHIBIT INDEX</b><br><br>
    </p>
<div style="text-align:left">
    <table style="margin-bottom: 10.0px; font-family: Times New Roman; font-size: 10pt; width: 100%" cellspacing="0">
      <tr>
        <td style="text-align: center; border-bottom: solid black 1.0pt; padding-left: 0.0px; width: 10%" valign="top">
          <p style="margin-bottom: 0px; margin-top: 0px">
            <b>Exhibit No.</b>
          </p>
        </td>
        <td style="text-align: left; padding-bottom: 2.0px; padding-left: 0.0px; width: 2%" valign="top">
          &#160;
        </td>
        <td style="text-align: center; border-bottom: solid black 1.0pt; padding-left: 0.0px; width: 88%" valign="top">
          <p style="margin-bottom: 0px; margin-top: 0px">
            <b>Description</b>
          </p>
        </td>
      </tr>
      <tr>
        <td style="width: 10%">

        </td>
        <td style="width: 2%">

        </td>
        <td style="text-align: left; padding-left: 0.0px; width: 88%" valign="top">
          &#160;
        </td>
      </tr>
      <tr>
        <td style="text-align: center; padding-right: 0.0px; padding-left: 0.0px; white-space: nowrap; width: 10%" valign="top">
          99.1
        </td>
        <td style="width: 2%">

        </td>
        <td style="text-align: left; padding-left: 0.0px; width: 88%" valign="top">
          <p style="margin-bottom: 0px; margin-top: 0px">
            Press release issued by Anika Therapeutics, Inc. on February 19,
            2015.
          </p>
        </td>
      </tr>
    </table>
    </div>
    <p>

    </p>
  </body>
</html>
<!--<!DOCTYPE html
     PUBLIC "-//W3C//DTD XHTML 1.0 Strict//EN"
     "http://www.w3.org/TR/xhtml1/DTD/xhtml1-strict.dtd">-->
<!--<!DOCTYPE html     PUBLIC "-//W3C//DTD XHTML 1.0 Strict//EN"     "http://www.w3.org/TR/xhtml1/DTD/xhtml1-strict.dtd">-->
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>a51043717ex99_1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<html>
  <head>
    <title></title>
<!--Copyright 2015 Business Wire, a Berkshire Hathaway company.-->
<!--All rights reserved www.businesswire.com-->
  </head>
  <body style="font-family: Times New Roman; font-size: 8pt">
    <p style="text-align: right">
      <b>Exhibit 99.1</b>
    </p>
    <p style="text-align: center">
      <font style="font-size: 12pt; font-family: Times New Roman"><b>Anika
      Therapeutics Appoints Dr. Glenn Larsen to its Board of Directors</b></font>
    </p>
    <p>
      BEDFORD, Mass.--(BUSINESS WIRE)--February 19, 2015--Anika Therapeutics,
      Inc. (Nasdaq: ANIK) today announced that it has appointed Glenn R.
      Larsen, Ph.D., as a new independent member of its Board of Directors.
      Dr. Larsen has extensive experience in the discovery, research and
      development of biologics, small molecule therapeutics and drug delivery
      medical devices for diverse clinical indications. Anika&#8217;s Board of
      Directors has voted to nominate Dr. Larsen for election by the
      stockholders at the 2015 Annual Meeting.
    </p>
    <p>
      &#8220;Glenn Larsen&#8217;s more than 30 years of scientific and executive
      management experience in pharmaceutical, biotech, orthopedics and
      regenerative medicine will be a valuable asset to Anika and its board,&#8221;
      said Charles H. Sherwood, Ph.D., president and chief executive officer.
      &#8220;We are excited to welcome Glenn to the board and look forward to
      benefiting from his strong technical expertise as well as his business
      insight going forward.&#8221;
    </p>
    <p>
      Dr. Larsen, age 60, is Chief Executive Officer of Aquinnah
      Pharmaceuticals, Inc., a pharmaceutical company focused on the
      development of treatments for neurodegenerative diseases, which he
      co-founded in February 2014. He also is a co-founder and Chairman of the
      Board of Directors of 180 Therapeutics L.P., a clinical stage drug
      delivery and development company founded in 2013. He previously served
      as Chief Scientific Officer and Executive Vice President of Research and
      Development at SpringLeaf Therapeutics, Inc., a producer of drug
      delivery devices, and at Hydra Biosciences, Inc., a biopharmaceutical
      company, as Chief Operating Officer, Executive Vice President of
      Development, and a member of its board of directors. During his prior
      employment at Wyeth/Genetics Institute, Dr. Larsen served in various
      research and development leadership positions, including directing
      Wyeth&#8217;s second largest therapeutic area as Vice President
      Musculoskeletal Sciences. Dr. Larsen received his Ph.D. in Biochemistry
      from Stony Brook University.
    </p>
    <p>
      <b>About Anika Therapeutics, Inc.</b>
    </p>
    <p>
      Headquartered in Bedford, Mass., Anika Therapeutics, Inc. develops,
      manufactures and commercializes therapeutic products for tissue
      protection, healing and repair. These products are based on hyaluronic
      acid (HA), a naturally occurring, biocompatible polymer found throughout
      the body. Anika's products range from orthopedic/joint health solutions
      led by Orthovisc<sup>&#174;</sup> and Monovisc<sup>&#174;</sup>,
      treatments for osteoarthritis of the knee, to surgical aids in the
      anti-adhesion and ophthalmic fields. The Company also offers aesthetic
      dermal fillers for the correction of facial wrinkles. Anika's Italian
      subsidiary, Anika Therapeutics S.r.l., provides complementary HA
      products in orthopedic/joint health and anti-adhesion, as well as
      therapeutics in areas such as advanced wound treatment and ear, nose and
      throat care. Its regenerative technology advances Anika's vision to
      offer therapeutic products and medical solutions that go beyond pain
      relief to protect and restore damaged tissue.
    </p>
    <p>
      CONTACT:<br>Anika Therapeutics, Inc.<br>Charles H. Sherwood, Ph.D.,
      President and CEO, 781-457-9000<br>or<br>Sylvia Cheung, CFO, 781-457-9000
    </p>
  </body>
</html>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
